Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

@article{Body2004OralIR,
  title={Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies},
  author={J. J. Body and Ingo Jakob Diel and M R Lichinitzer and Alexander F Lazarev and Martin Pecherstorfer and Richard Bell and Debu Tripathy and Bengt Bergstrom},
  journal={British Journal of Cancer},
  year={2004},
  volume={90},
  pages={1133 - 1137}
}
Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for many patients due to infusion-related adverse events (AEs), an increased risk of renal toxicity and the inconvenience of regular hospital visits. The use of oral bisphosphonate therapy is limited by concerns over efficacy and gastrointestinal (GI) side effects. There remains a clinical need for an oral bisphosphonate that offers equivalent efficacy to i.v… CONTINUE READING